This study aimed to assess serum S100A8 for APS diagnosis and risk stratification among aPL carriers.<h4>Methods</h4>Serum S100A8 levels were measured by ELISA in healthy controls (HCs), aPL carriers without manifestation and patients with APS. This evidence concerns the gene S100A8 and autoimmune polyendocrinopathy.